A subset of ovarian cancer cell lines and patient-derived models are sensitive to PARG inhibitor (PARGi) monotherapy, and importantly sensitivity is neither mutually exclusive nor perfectly overlapping with PARPi-sensitivity, suggesting that a distinct cell cycle vulnerability leads to PARGi-sensitivity (12,15). This evidence concerns the gene PARG and ovarian carcinoma.